A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Exclusion Criteria

• •In the opinion of the investigator, the participant's life expectancy is less than or equal to (\<=) 5 years.
• •The participant has undergone or is scheduled to undergo kidney transplantation or is currently on dialysis, or has any signs or symptoms of end stage renal disease.
• •Urine protein/creatinine ratio (PCR) greater than (\>) 1.5 milligram per milligram (mg/mg).
• •Participants who have clinically relevant history of allergy or signs or symptoms of severe hypersensitivity, (including hypersensitivity to the REPLAGAL active substance or any of the excipients), which in the investigator's judgment, will substantially increase the participant's risk if he or she participates in the study.
• •Cardiac fibrosis involving more than 2 segments, as determined by cMRI at screening.
• •In the opinion of the investigator, the participant has non-Fabry disease-related cause of end-organ (renal, cardiac, central nervous system) dysfunction/failure or is receiving medications that may affect the rate of disease progression, as assessed by cardiac and/or renal measures.
• •The participant has a positive test at screening for hepatitis B surface antigen, positive test for hepatitis B core antibody, positive test for hepatitis C (HCV) antibody with confirmation by HCV-ribonucleic acid polymerase chain reaction testing, or positive test for human immunodeficiency virus antibody.
• •Treatment with REPLAGAL at any time prior to the study.
• •Prior treatment with any of the following medications:
• •1. FABRAZYME (agalsidase beta) and its biosimilars
• •2. GLYSET (miglitol)
• •3. ZAVESCA (miglustat)
• •4. CERDELGA (eliglustat)
• •5. GALAFOLD (migalastat)
• •6. Any investigational product for treatment of Fabry disease
• •Treatment at any time during the study with the following medications:
• •1. Chloroquine
• •2. Amiodarone
• •3. Monobenzone
• •4. Gentamicin
• •The participant is pregnant or lactating.
• •The participant has a body mass index \> 39 kilogram per square meter (kg/ m\^2). (Body mass index \[BMI\] = kg/ m\^2).
• •The participant is treated or has been treated with any investigational drug within 30 days of study start.
• •The participant is unable to understand the nature, scope, and possible consequences of the study.
• •The participant is unable to comply with the protocol, eg, uncooperative with protocol schedule, refusal to agree to all of the study procedures, inability to return for evaluations, or is otherwise unlikely to complete the study, as determined by the investigator.